| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5642701 | Oral Oncology | 2017 | 9 Pages |
Abstract
R/M SCCHN patients with an inflamed tumor immunophenotype demonstrate improved survival. Further prospective studies are needed to validate these findings and explore the use of immunophenotype to guide patient selection for immunotherapeutic approaches.
Related Topics
Health Sciences
Medicine and Dentistry
Dentistry, Oral Surgery and Medicine
Authors
Glenn J. Hanna, Hongye Liu, Robert E. Jones, Alyssa F. Bacay, Patrick H. Lizotte, Elena V. Ivanova, Mark A. Bittinger, Megan E. Cavanaugh, Amanda J. Rode, Jonathan D. Schoenfeld, Nicole G. Chau, Robert I. Haddad, Jochen H. Lorch, Kwok-Kin Wong,